Proton Benefits

Clinical Studies

The body of strong, clinical evidence illustrating the benefits of proton therapy continues to grow. Provision and other medical centers participate in many ongoing clinical trials and research initiatives to expand our understanding of the disease sites for which proton therapy is the best treatment option and the benefits it gives different patient populations. Many proton therapy trials have been completed and have yielded compelling results.

Download Infographic

Brain Cancer

Clinical Benefits of Proton Therapy:

  • 31% increase in disease control for aggressive tumors at base of skull (chordomas) at 5 years.1
  • 50% less likely to have secondary brain tumor from treatment.2
  • 55% reduction in average dose to the hippocampi (memory function) in treatment of meningioma.3

Sources and Studies:

1. Effectiveness and Safety of Spot Scanning Proton Radiation Therapy for Chordomas and Chondrosarcomas of the Skull Base: First Long-Term Report. Read More

2. A comparison of critical structure dose and toxicity risks in patients with low grade gliomas treated with imrt versus proton radiation therapy. Read More

3. Projected second tumor risk and dose to neurocognitive structures after proton versus photon radiotherapy for benign meningioma. Read More

Prostate Cancer

Clinical Benefits of Proton Therapy:

  • 5% higher 5-year overall survival in intermediate risk.1
  • Patients who received proton therapy report highest quality of life compared to surgery, x-ray, or brachytherapy patients.2
  • 35% less radiation to the bladder and 59% less radiation to the rectum.3
  • 42% reduction in relative risk of developing a secondary malignancy.4
  • 50% reduction in treatment related bowel frequency and urgency at 2 years.5
  • 21% lower risk of urinary toxicity at 2 years.5
  • 25% lower risk of erectile dysfunction at 2 years.6

Sources and Studies:

1.Proton Therapy Is Associated with Superior Survival and Decreased Risk of Complications Compared to IMRT for Intermediate Risk Prostate Cancer: A Medicare/SEER Database Study.

2.Bryant Survey Results.

3.Dose–Volume Comparison of Proton Therapy and Intensity-Modulated Radiotherapy for Prostate Cancer. Read More

4.Proton Therapy Is Associated with Superior Survival and Decreased Risk of Complications Compared to IMRT for Intermediate Risk Prostate Cancer: A Medicare/SEER Database Study.

5.Comparative Effectiveness Study of Patient-Reported Outcomes following Proton Therapy or IMRT for Prostate Cancer. Read More

6.Comparative toxicity and cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. Read More

Breast Cancer

Clinical Benefits of Proton Therapy:

  • 88% less radiation dose to the heart for left sided breast cancer.1,2
  • 44% reduction in clinically significant radiation doses to the lung.2
  • 90% of partial breast irradiation cases result in good to excellent cosmetic outcomes at 5 years.3
  • Well tolerated – Less than 4% serious side effects (grade 3) in locally advanced breast cancer.2

Sources and Studies:

1.Phase III randomized trial proton vs photon therapy for patients with non-metastatic breast cancer receiving comprehensive nodal radiation: A radiotherapy comparative effectiveness (RADCOMP) Consortium trial. Read More

2.Early Toxicity in Patients Treated With Postoperative Proton Therapy for Locally Advanced Breast Cancer. Read More

3.Partial Breast Radiation Therapy With Proton Beam: 5-Year Results With Cosmetic Outcomes. Read More

Lung Cancer

Clinical Benefits of Proton Therapy:

  • 35% relative increase in overall survival for Stage II & III lung cancer.1
  • 56% relative reduction in incidences of serious (grade 3) pain with swallowing (esophagitis).2
  • Up to 4-week reduction in treatment time for select cases.3

Sources and Studies:

1.National Cancer Database Analysis of Proton Versus Photon Radiaion Therapy in NSCLC. Read More

2.Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non–Small Cell Lung CancerFinal Results of a Phase 2 Study. Read More

3.High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center. Fractionation 10 for PBT vs 6-8 weeks for IMRT. Read More

Head and Neck Cancers

Clinical Benefits of Proton Therapy:

  • 27% reduction in overall risk of needing a feeding tube for oropharyngeal cancer.1
  • Less side effects first 3 months after treatment, quicker return to normal function in patients with oropharyngeal cancer.2
  • 45% reduction in overall risk of needing a feeding tube for nasopharyngeal cancer.3
  • Dramatic reduction of negative impact on taste, nausea, and painful changes to the mouth in salivary gland treatment.4
  • 44% relative increase in disease free survival rate for nasal and paranasal sinus cavity cancers at 5 years.5

Sources and Studies:

1.Gastrostomy Tubes Decrease by Over 50% With Intensity Modulated Proton Therapy (IMPT) During the Treatment of Oropharyngeal Cancer Patients. Read More

2.Intensity Modulated Proton Therapy Versus Intensity Modulated Photon RT for Oropharyngeal Cancer: First Comparative Results of Patient Reported Outcomes. Read More

3.Proton therapy reduces treatment-related toxicities for patients with nasopharyngeal cancer: a case-match control study of IMPT and IMRT. Read More

4.Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation. Read More

5.Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. Read More

Esophageal Cancer

Clinical Benefits of Proton Therapy:

  • 10% increase in overall survival at 5 years in stage I-III disease.1
  • 10% increase in local cancer control at 5 years in stage II-III.1
  • 15% decrease in distant metastasis at 5 years in stage II-III.1
  • 26% reduction in pulmonary toxicity compared with X-ray therapy (IMRT).2
  • 21% reduction in the risk of severe, treatment related lymphopenia, particularly in lower esophagus.3
  • 3-4-day reduction in average hospital stay after surgery.4

Sources and Studies:

1.Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus IMRT for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Read More

2.A Multi-Institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients. Read More

3.Lymphocyte-sparing Effect of proton therapy in patients with esophageal cancer treated with definitive chemoradiation. Read More

4.Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. Read More

Rectal/Anal Cancers

Clinical Benefits of Proton Therapy:

  • More than 50% reduction in radiation dose to critical structures including bone marrow.1

Sources and Studies:

1.Scanning proton beam therapy reduces normal tissue exposure in pelvic radiotherapy for anal cancer. Read More

Liver Cancer

Clinical Benefits of Proton Therapy:

  • Associated with excellent local control and favorable survival rates.1
  • Able to treat larger tumors (>6cm) ineligible for stereotactic radiation (SBRT) or ablation.1

Sources and Studies:

1.Multi-Institutional Phase II Study of High Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Read More

Request Information

For information or to schedule a consultation, contact us to speak with a Care Coordinator.

Partner With Us

For general information or to learn about our collaborative partnerships, future developments, ProNova proton therapy system, or investment opportunities, contact us.